Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Short-term Investments: 2017-2025

Historic Short-term Investments for Dr Reddys Laboratories (RDY) over the last 9 years, with Mar 2025 value amounting to $506.0 million.

  • Dr Reddys Laboratories' Short-term Investments fell 43.27% to $506.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $506.0 million, marking a year-over-year decrease of 43.27%. This contributed to the annual value of $506.0 million for FY2025, which is 43.27% down from last year.
  • Dr Reddys Laboratories' Short-term Investments amounted to $506.0 million in Q1 2025, which was down 43.27% from $892.0 million recorded in Q1 2024.
  • In the past 5 years, Dr Reddys Laboratories' Short-term Investments registered a high of $892.0 million during Q1 2024, and its lowest value of $270.0 million during Q1 2021.
  • Moreover, its 3-year median value for Short-term Investments was $682.0 million (2023), whereas its average is $693.3 million.
  • In the last 5 years, Dr Reddys Laboratories' Short-term Investments soared by 75.32% in 2023 and then tumbled by 43.27% in 2025.
  • Dr Reddys Laboratories' Short-term Investments (MRQ) stood at $270.0 million in 2021, then skyrocketed by 44.07% to $389.0 million in 2022, then skyrocketed by 75.32% to $682.0 million in 2023, then soared by 30.79% to $892.0 million in 2024, then tumbled by 43.27% to $506.0 million in 2025.
  • Its last three reported values are $506.0 million in Q1 2025, $892.0 million for Q1 2024, and $682.0 million during Q1 2023.